Shares of Accenture plc (NYSE:ACN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-three ...

Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Accenture (ACN) reachead $380.75 at the closing of the latest trading day, reflecting a +1.69% change compared to its last close.

(HealthDay News) — A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk US population, according to a study presented at the American ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where ...

A team from the University of Geneva and Bayer AG present their findings on the on-off retention of oligonucleotides and the ...

In a report released today, Jason Kupferberg from Bank of America Securities maintained a Buy rating on Accenture (ACN – Research Report). The ...

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Accenture (ACN – Research Report) and Itron ...

The long-awaited and elusive ceasefire between Israel and Hamas has silenced bombs and halted air raids on the Gaza Strip, ...

ACN's vague AI strategy and overvaluation by the market suggest potential revenue struggles, with 2025 growth projections likely to be over-optimistic. The company's earnings are a weak proxy for ...